Covid-19 vaccines: what they mean for people with MS
12 November 2020
We speak to a neurologist about whether a future Covid-19 vaccine would be safe and effective for people with MS.
A round-up of research from MS Virtual 2020
4 November 2020
An update from the this ECTRIMS and ACTRIMS which is the largest annual MS research conference.
Siponimod (Mayzent) approved for active secondary progressive MS in England and Wales
15 October 2020
The MS Trust is delighted that siponimod (Mayzent) has also been approved by NICE in England and Wales.
Siponimod (Mayzent) approved for active secondary progressive MS in Scotland
12 October 2020
The MS Trust is delighted that siponimod (Mayzent) has been approved in Scotland for people with SPMS continuing to have relapses or show signs of MS activity on MRI scans.
Trial reports myelin repair success
25 September 2020
Repairing the damage to nerves caused by MS is possible, according to research presented at the MS Virtual 2020 conference.
Health Technology Wales guidance for AHSCT
28 August 2020
Health Technology Wales published a report supporting the routine use of autologous haematopoietic stem cell transplantation (AHSCT) for people with RRMS, who have recurrent symptoms despite treatment with disease modifying drugs.
Round-up of research on coronavirus, Covid-19 and multiple sclerosis
29 June 2020
We’ve been sifting through the research up to the end of June to bring you a round-up of the studies that give an idea of what coronavirus means to people with MS.
Siponimod for active secondary progressive MS rejected by Nice
25 June 2020
In its initial decision, Nice is unable to recommend siponimod (Mayzent) for active secondary progressive MS as an NHS treatment in England and Wales.
Preliminary research on Covid-19 in people with MS in Italy offers some reassurance
1 May 2020
People with multiple sclerosis who contracted Covid-19 did no worse than the general population according to preliminary results from Italy.
Learning a second language improves brain structures in MS
20 April 2020
In this study, researchers investigated whether people with MS gain cognitive benefits from learning a new language.
Brain training: a cognitive rehabilitation programme evaluated
7 April 2020
In this research, a programme designed to improve cognitive skills, such as memory, concentration and problem solving, was tested in a large clinical trial.
Ozanimod (Zeposia) recommended for European licence
1 April 2020
Ozanimod (Zeposia) has been recommended for licensing by the European Medicines Agency.